Philikos B.V.: Philikos announces initiation of clinical Phase 1/2 study with T-Guard in patients with systemic sclerosis

NIJMEGEN, the Netherlands, May 20, 2025 (GLOBE NEWSWIRE) -- Philikos B.V., a Dutch biotechnology company developing antibody-based therapies to treat severe immune disorders, today announced that it has enrolled the first patient in a Phase 1/2 clinical trial designed to evaluate the use of T-Guard for the treatment of patients with diffuse cutaneous systemic sclerosis (dcSSc), a serious autoimmune disorder with limited treatment options.

This open-label, single-arm Phase 1/2 clinical trial (PHIL_TG-01; EU CT: 2024-517283-28-00) aims to assess the safety and preliminary efficacy of T-Guard in early-stage dcSSc patients. The study is planned to enroll 12 adult patients who have been diagnosed within the last three years with dcSSc and whose disease remains refractory despite prior systemic immunosuppressive therapy.

The primary endpoint of the study is the incidence of grade 3 or higher adverse events occurring from the first T-Guard infusion through 28 days after the last T-Guard administration. T-Guard is administered over a one-week period, consisting of four infusions given every other day. Secondary endpoints include improvement in dcSSc disease, as measured by the Revised Composite Response Index in Systemic Sclerosis (CRISS) at 1, 3, 6, 9 and 12 months post treatment initiation.

"We are excited to initiate this trial, which represents a major step forward in bringing T-Guard to patients suffering from diffuse cutaneous systemic sclerosis, a significant unmet medical need where T-Guard may qualify for orphan drug designation," said Ypke van Oosterhout, Ph.D., Chief Executive Officer of Philikos. "We strongly believe that T-Guard has the potential to be an alternative solution to an expensive and risky hematopoietic stem cell transplantation, the only curative treatment option today. With its short treatment duration, targeted immune depletion, and anticipated good tolerability, T-Guard could offer a less invasive and more accessible option for a broader group of patients suffering from this devastating disease."

"With no widely accessible and safe disease-modifying treatments available, there is a high unmet medical need for effective new therapies for systemic sclerosis," said Principal Investigator (PI) Madelon Vonk, M.D., Ph.D., Associate Professor Systemic Sclerosis at Radboud University Medical Center (Radboudumc). "T-Guard, with promising preclinical data and initial clinical results, has the potential to significantly impact patients suffering from this debilitating and life-threatening autoimmune disease characterized by inflammation and fibrosis."

The study will begin with four patients, after which an independent Data Safety Monitoring Board (DSMB) will assess safety and preliminary efficacy. If the balance between adverse effects and efficacy is positive, the study will be expanded to include a total of 12 participants. Interim data and the recommendation of the DSMB are expected by the end of 2025.

About systemic sclerosis (SSc)

Systemic sclerosis (SSc) is a serious autoimmune disorder characterized by vascular damage, skin tightening, and hardening of connective tissue (fibrosis) in various internal organs. SSc has two subtypes: limited cutaneous (lcSSc) and diffuse cutaneous (dcSSc). SSc affects approximately 200,000 patients in the seven major markets, 67,000 of whom have dcSSc, the more severe form. The prognosis for dcSSc is less favorable due to a higher risk of life-threatening complications, such as interstitial lung disease (ILD), which severely impairs lung function. Most treatments for dcSSc are aimed at suppressing the immune system. To date, hematopoietic stem cell transplantation (HSCT) - which involves a deep and non-specific clearing of immune cells and regenerating them with transplanted stem cells - is the only approach shown to halt the disease process. However, HSCT is associated with severe side effects and a 5-10% risk of mortality and is accessible to only a fraction of dcSSc patients.

T-Guard: helping reset the body's immune system

T-Guard is designed to rapidly and safely reset the body's immune system in life-threatening T-cell mediated conditions such as severe autoimmune diseases. It is an off-the-shelf therapy that is administered as a short one-off treatment that will be dispensed over one week, consisting of four infusions given every other day. T-Guard is a unique combination of toxin-conjugated monoclonal antibodies that target CD3 and CD7 molecules on T cells and NK cells. Laboratory studies have shown that T-Guard can eliminate disease-associated T cells and NK cells from the blood and tissues of SSc patients. In addition, T-Guard treatment of a patient with advanced dcSSc on a compassionate use basis showed encouraging results. Philikos also has a solid late-stage clinical data package with T-Guard from earlier work done in the most severe form of acute graft-versus-host disease.

About Philikos B.V.

Philikos, a privately held biotechnology company based in the Netherlands, is developing antibody-based therapies for the treatment of severe immune disorders. The company's platform offers a compound, T-Guard, that rebalances the immune system by depleting activated T cells and NK cells, enabling patients with autoimmune diseases such as scleroderma to achieve restored immune functions and improved long-term health outcomes. Philikos is backed by early-stage investors: Oost NL, Essential Investments, and Radboud University Medical Center (Radboudumc), with which it also maintains a strong research collaboration.

For more information, please visit us at www.philikos.com.

Contacts:
Corporate	Media Relations
Philikos B.V. Ypke van Oosterhout, Ph.D. Founder and Chief Executive Officer Phone: [phone] Email: [e-mail] (mailto:[e-mail])	MC Services AG Solveigh Mähler, Ph.D. Phone: [phone] Email: [e-mail] (mailto:[e-mail])
	For U.S. inquiries: Laurie Doyle Phone: [phone] Email: [e-mail] (mailto:[e-mail])